drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Bispecific T-cell engager (BiTE) biologic that binds CD19 on B-lineage cells and CD3 on T cells, redirecting cytotoxic T cells to eliminate CD19+ leukemia/minimal residual disease.
nci_thesaurus_concept_id
C62528
nci_thesaurus_preferred_term
Blinatumomab
nci_thesaurus_definition
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.
drug_mesh_term
Blinatumomab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Blinatumomab is a bispecific CD19×CD3 antibody (BiTE) that bridges CD19+ B-lineage cells and CD3+ T cells, forming an immunologic synapse that activates and redirects cytotoxic T cells to lyse CD19-expressing leukemia cells and clear minimal residual disease, independently of MHC.
drug_name
Blinatumomab
nct_id_drug_ref
NCT06658938